DFTX
The table below shows Definium Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$131.56M | -$79.13M | -$64.36M | -$50.14M | -$45.82M | -$23.60M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | -$151.61M | $0.00 | - | - | -$297.00K | - |
| Dividends paid | - | - | - | - | - | - |
Definium Therapeutics, Inc. reported operating cash flow of -$131.56M for fiscal year 2025. That is down 66.3% from -$79.13M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$23.60M (FY 2020) to -$131.56M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $267.27M | $253.20M | $21.85M | $59.05M | $98.82M | $96.70M |